[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipidemia":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100609824",false,"NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[26,27,28],"Lipidemia","Type 2 Diabetes (T2DM)","Metabolic Syndrome (MetS)","RECRUITING","2026-03-06",{"date":32,"type":33},"2026-03-10","ACTUAL",{"date":35,"type":33},"2025-12-11",{"date":37,"type":20},"2028-06",{"name":39,"class":40},"NewAmsterdam Pharma","INDUSTRY",20,""]